A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors
This is the first in human study of QLP2117. To evaluate the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in patients with advanced solid tumors.
Advanced Solid Tumors
DRUG: QLP2117
Dose-limiting toxicity(DLT), 21days|Percentage of Participants Experiencing Adverse Events (AEs) According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, up to 96 weeks|Objective Response Rate for phase 1b, up to 96 weeks
This is the first in human study of QLP2117. To evaluate the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in patients with advanced solid tumors.